The FDA originally approved Sermorelin (under the brand name Geref) for diagnostic testing of pituitary function
Declining estrogen and testosterone levels can lead to vaginal dryness, mood swings, sleep disturbances, and reduced sex drive
Side Effect CJC-1295 + Ipamorelin HGH (Somatropin) Injection site reactions Common, mild Common, mild Water retention/edema Mild, transient Moderate to significant, dose-dependent Joint pain Rare Common at higher doses (carpal tunnel, arthralgia) Insulin resistance Not documented as significant Well-documented at supraphysiological doses Cortisol elevation Minimal (Ipamorelin is selective) Not directly caused by HGH Prolactin elevation Minimal (Ipamorelin advantage over GHRP-2/6) Not directly caused by HGH Organ enlargement risk Not documented (physiological GH levels) Documented at chronic supraphysiological doses Pituitary suppression Feedback loop preserved Natural GH production suppressed with prolonged use The side effect differential largely stems from the feedback loop distinction
Together, they deliver synergistic results with lower risk of suppression or estrogenic side effects (compared to AAS)
Palmieri F: Diseases caused by defects of mitochondrial carriers: a review